Background. Although enteroviruses and adenoviruses are considered to be the leading causes of the usually mild clinical myocarditis, little is known about the etiology of severe or fatal myocarditis.
pesviridae family, cytomegalovirus (CMV) [8] , and human herpesvirus 6 (HHV-6) [9] have occasionally been associated with myocarditis. In immunosuppressed patients and heart transplant recipients, CMV is a common cause of cardiac infection [10, 11] .
Although the causes of the usually benign clinical myocarditis have been extensively studied [12] , the etiology of severe or fatal myocarditis has remained obscure. We set out to study the viral etiology of fatal myocarditis in a retrospective, population-based study using PCR and in situ hybridization methods.
METHODS

Patients and specimens.
We collected all death certificates with myocarditis recorded as the underlying cause of death from the period of 1970-1998 in Finland ( ) from the Statistics Finland database. Autopsy n p 639 protocols, hospital records, and myocardial autopsy samples were requested for these cases and were received for 142 cases. Of these, findings for all 40 patients (20 men and 20 women; median age, 49 years; age range, 7 months to 79 years) whose cases fulfilled the histopathologic Dallas criteria for active myocarditis in histopathologic reanalysis (figure 1) [13] and whose myocardial autopsy samples contained preserved nucleic acids (detected as described in "Molecular analyses") were included in this study. Clinical features were retrospectively evaluated with use of the hospital records and all other available clinical information. Eighteen age-and sexmatched subjects who had died accidentally were selected for the control group. Myocardial autopsy samples obtained from 12 control subjects (7 men and 5 women; median age, 53 years; age range, 8 months to 73 years) contained preserved nucleic acids and were included in this study. The local ethics committee and the Finnish Ministry of Social Affairs and Health (Helsinki) approved the conduct of the study.
Nucleic acid extraction. Five 5-mm sections were cut from paraffin-embedded cardiac tissues with use of sterile techniques and were placed into Eppendorf tubes. The sections were deparaffined with 2 washes in xylene followed by 2 rinses in ethanol. Nucleic acids were isolated with a commercial extraction kit (High Pure Viral Nucleic Acid Kit; Roche Diagnostics) in accordance with the manufacturer's instructions.
Molecular analyses. Myocardial samples were examined for adenovirus, CMV, enterovirus, HHV-6, influenza viruses A and B, parvovirus B19, and rhinovirus genomes by use of PCR assays in accordance with standard protocols in the viral diagnostic laboratory at the Department of Virology, University of Turku (Turku, Finland). The methods used have been described elsewhere [14] [15] [16] [17] [18] , except for those used for influenza A and B viruses. Influenza A and B PCR was performed using Titan One Tube RT-PCR system (Roche Diagnostics). Primer sequences were as follows: influenza A H1 (+), 5 -GATACTGA-GCTCAATTGCTC-3 ; influenza A H1 (Ϫ), 5 -ATGCAGACAC-AATATGTATAGGC-3 ; influenza A H3 (+), 5 -GAGCTGGTT-CAGAGTTCCTC-3 ; influenza A H3 (Ϫ), 5 -GTGACCTAAG-GGAGGCATAATC-3 ; influenza B (+), 5 -GTAAACACCCAC-ATTCCAAACG-3 ; and influenza B (Ϫ), 5 -GAAGTAGGTGG-AGACGGAGGG-3 . Amplification of PCR-negative samples with human b-actin primers was performed to show the presence of cellular nucleic acids in the specimens [19] , and only specimens with a positive signal were included in the study.
Because a tissue sample may have positive PCR results because of viremia or circulating blood cells harboring virus, in situ hybridization was performed for the samples with PCR results positive for CMV, HHV-6, and parvovirus B19. In situ hybridizations were also performed for PCR-negative samples obtained from control subjects. A digoxigenin-labeled total genome-isolated DNA probe (Panpath) was used for CMV hybridization, a bionylated oligoprobe (Qiagen) was used for HHV-6 hybridization, and a digoxigenin-labeled amplification product of a parvovirus PCR from a parvovirus-positive serum sample was used for parvovirus B19 hybridization. The CMV and HHV-6 hybridization procedures were modifications of previously described protocols [20, 21] . In short, after deparaffination and hybridization, the slides for CMV in situ hybridization assays were incubated with an alkaline phosphataseconjugated anti-digoxigenin antibody (Roche Diagnostics). The HHV-6 in situ hybridization assay was performed using a rabbit anti-biotin antibody (Enzo), followed by use of a second biotinylated anti-rabbit IgG (Vector Lab) and streptavidin-alkaline phospatase conjugate (Zymed). For both CMV and HHV-6 in situ hybridizations, 4-nitro blue tetra-zolium chloride, 5-bromo-4-chloro-3-indolyl-phosphate, toluidine salt (NBT-BCIP; Roche Diagnostics) was used as a substrate, and hemalum was used as a counterstain. Parvovirus B19 in situ hybridization was performed using the Ventana Discovery in situ hybridization automate (Ventana Medical Systems) and the "Research ISH BlueMap" protocol. The samples were treated with Ventana protease 2 reagent for 6 min and were hybridized for 12 h at 57ЊC. After washes at 65ЊC for 6 min with 2ϫ sodium chloridesodium citrate buffer (SSC), 0.1ϫ SSC, and 0.1ϫ SSC, the slides were incubated with biotinylated anti-digoxigenin antibody (Jackon ImmunoResearch), and the signal was developed with NBT-BCIP. The slides were counterstained with nuclear fast red. The positive signals of the in situ hybridizations were seen as a dark, spotted nuclear staining.
Statistical analyses. Differences between groups were analyzed with use of Student's t test and x 2 analysis with SPSS software, version 11 (SPSS). Differences were considered to be statistically significant at . P ! .05
RESULTS
Clinical cardiac symptoms had been present for a median 3.5 days (range, !1 to 90 days) before death (table 1) . On the basis of clinical records, 45% of the patients were found to have died of progressive heart failure, whereas death was found to have been caused by other mechanisms (mainly cardiac arrest) in 48% of patients. Three patients had been found dead. Signs and symptoms of infectious disease had been recorded in 26 patients (65%). Previous cardiac or systemic disease capable of affecting the myocardium had been present in 17 patients (43%) (table  1 ). An immunocompromising condition or treatment had been present in or received by 3 patients (8%) (table 1). None of the control subjects had any evidence of an immunocompromising condition or receipt of immunocompromising treatment. Viral genomes were found by PCR in the cardiac samples of 17 (43%) of 40 patients who had died of myocarditis (table 1) . The most common single finding was the presence of CMV. CMV DNA was detected in the myocardial specimens from 15 patients (38%). Parvovirus B19 DNA was amplified in the samples from 4 patients (10%), of which 3 samples also yielded positive results of the CMV PCR assay. In 1 patient (3%), CMV was simultaneously detected with enterovirus. Human herpesvirus 6 was detected in 1 patient. No adenovirus, influenza virus A or B, or rhinovirus genomes were found in the heart samples from the patients with fatal myocarditis. The patients with positive CMV PCR results were younger than the other patients with fatal myocarditis (mean age ‫ע‬ SEM, vs. years; 34 ‫ע‬ 7 ‫ע15‬ 5 ). In contrast, no differences in sex or clinical features P p .049 were found between the patients with positive viral PCR (particularly CMV PCR) results and the patients with negative PCR results. Samples for 1 immunocompromised patient yielded positive CMV PCR results. In control subjects, viral genomes were detected in only 2 cases (17%). Parvovirus B19 DNA was found in samples from a 70-year-old woman, and HHV-6 DNA was found in samples from a 68-year-old woman. No evidence of adenovirus, CMV, enterovirus, influenza virus A or B, or rhinovirus infection was found in samples from the control subjects.
A positive signal in CMV in situ hybridization was observed in 12 (80%) of the 15 CMV PCR-positive samples (table 1) . Only interstitial cells yielded positive results by in situ hybridization in 2 specimens. In the other 10 patients, in situ hybridization revealed the localization of CMV DNA not only in interstitial cells, but also in cardiomyocytes (figure 2A). Parvovirus B19 DNA was found in both cardiomyocytes ( figure  2B ) and interstitial cells from all 4 PCR-positive patients. HHV-6 DNA was only detected in interstitial cells (table 1) . The samples from PCR-negative control subjects had negative results of in situ hybridization.
DISCUSSION
Results of this population-based study show that CMV infection of the heart is commonly associated with severe myocarditis in immunocompetent patients. Because there are effective antiviral therapies available for CMV infection, these findings may have important clinical implications for the treatment of severe myocarditis.
In developed countries, primary CMV infection occurs early in life, with the seroprevalence among adults being ∼70% [22] . Circulating CMV antibodies appear in ∼40% of Finnish children by the age of 7 years [23] . After primary infection, the virus persists in the body and is located mainly in leukocytes and endothelial cells. In immunocompetent subjects, primary infections, reactivations, and reinfections are usually asymptomatic, but there are also rare reports of severe and even fatal CMV infections in previously healthy children and adults [24] [25] [26] . In contrast, immunosuppressed patients and-especiallyorgan transplant recipients are prone to significant mortality and morbidity due to CMV infection [10, 11] .
CMV has a wide tissue tropism and is able to infect multiple organs, including the heart. Recently, an association between CMV and myocarditis in adolescents and adults has been pro- posed. PCR of heart samples (mainly biopsy specimens) of 11100 patients with active and borderline myocarditis revealed CMV DNA in 3% [27, 28] . Previous studies using in situ hybridization have detected CMV genome in cardiomyocytes in 0%-16% of endomyocardial biopsy specimens obtained from patients with active myocarditis [8, 29, 30] . These studies, however, did not state the immunostatus of the patients involved [8, 29, 30] . We found CMV genome to be present in 38% of patients with fatal myocarditis. The results of in situ hybridization assays for CMV were positive in 80% of these CMV PCR-positive samples and revealed the localization of viral DNA in cardiomyocytes in the majority of the samples. None of our specimens obtained from the control subjects harbored CMV DNA. Moreover, our study material consisted only of data from the most severe cases of myocarditis in mostly nonimmunocompromised patients. Thus, our results provide novel evidence of the importance of CMV as the cause of severe (fatal) myocarditis in immunocompetent subjects.
These findings call for investigations of the potential efficacy of antiviral therapy against CMV infection in persons with severe myocarditis. Antiviral treatments are known to be effective for the treatment of CMV disease in immunocompromised patients [31] . Treatment with ganciclovir or cidofovir has been shown to reduce the severity of acute murine CMV myocarditis [32] . Also, antiviral IFN-b has been shown to have beneficial effects in acute murine coxsackievirus myocarditis [33] and in patients with cardiomyopathy who have persistent enterovirus or adenovirus infection [34] .
Recently, 2 large studies that used PCR have suggested that 2 common causes of respiratory infections-namely, enteroviruses and adenoviruses-are the major causes of clinical myocarditis [27, 28] . We were unable to confirm these findings in a population-based study of cases with a fatal outcome. This implies that causes of fatal myocarditis may be different from the causes of the more common mild disease forms. Our results are in line with the previous finding that !1% of myocarditis cases were associated with influenza [28] .
Infection with parvovirus B19 has previously been associated with fatal myocarditis in children [35, 36] and adults [6, 7] , as well as with sudden infant death syndrome [37] . In a recent PCR-based study of endomyocardial biopsy specimens obtained from 48 adults with myocarditis or myopericarditis, 19% were found to be parvovirus B19 positive [38] . We found parvovirus B19 genome in 10% of the cardiac samples from patients with fatal myocarditis. Notably, the majority (75%) of these patients also had CMV DNA in their heart tissues, which may have contributed to the poor prognosis.
We used a retrospective study design because it made efficient etiological screening possible. A potential limitation of this approach is the possible degradation of nucleic acids in the heart samples due to fixation and long storage times [19, 39, 40] . The degradation of RNA is known to occur more easily than that of DNA [40] . In the present study, data from only 6 of the 46 cases that fulfilled the Dallas criteria in histopathologic reanalysis were excluded because of nucleic acid degradation. Although cellular nucleic acids of a housekeeping gene were found, it is still possible that we were unable to detect viral RNA as a result of marked degradation of viral genomes. We also had access to data from only a limited number of age-and sex-matched control subjects, possibly affecting the estimations of virus positivity in a healthy population. An additional limitation of the retrospective nature of our study is the availability of clinical data. For example, it is not possible to conclude whether the virus findings were connected with primary or reactivated latent infections.
In conclusion, CMV infection of the heart is common in cases of fatal myocarditis. This observation calls for investigations of the potential efficacy of antiviral therapy against CMV infection in patients with severe acute myocarditis.
